Use of an SGLT-2 inhibitor was also associated with a lower incidence of MACE in patients without CKD: RR 0.93 (95% CI 0.87–0.99; P = 0.03) (Fig. 3 and Table 3). The gene discussed is SLC5A2; the disease is chronic kidney disease.